Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from Poolbeg Pharma Ltd. ( (GB:POLB) ) is now available.
Poolbeg Pharma announced that all resolutions at its Annual General Meeting and General Meeting were passed, following a successful fundraising effort that raised £4.865 million. The company has applied for 197,200,000 new ordinary shares to be admitted to trading on AIM, with admission expected on 25 June 2025. This move will increase the company’s issued share capital to 697,200,000 ordinary shares, impacting shareholder voting rights and potentially enhancing the company’s market position.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. The company’s clinical programs target large addressable markets, including cancer immunotherapy-induced Cytokine Release Syndrome (CRS) and metabolic conditions such as obesity, with the development of an oral encapsulated GLP-1.
Average Trading Volume: 1,785,981
Technical Sentiment Signal: Hold
Learn more about POLB stock on TipRanks’ Stock Analysis page.